GET DAILY SIGNALSDocGo (DCGO) Reports Mixed Q3 Results as Revenue Misses Estimates
Key Takeaways
- DocGo reported third quarter 2026 revenue of $73.4 million, up 3.7% year over year but below Wall Street's roughly $78.7 million consensus estimate.
- Net loss narrowed to $18.1 million from $29.7 million a year earlier, while adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) improved to a loss of $3.2 million from a loss of $7.2 million.
- Diluted loss per share of $0.17 came in wider than the approximately $0.09 loss that analysts had expected.
- Medical transportation revenue reached a quarterly record of $53.3 million, while Mobile Health revenue declined slightly to $20.2 million.
- Management cut full-year 2026 revenue guidance to approximately $300 million and kept adjusted EBITDA guidance unchanged at a loss of $17 million to $22 million.
- The company also announced a CEO transition, with the board launching a search as Lee Bienstock's contract nears its December 31, 2026 expiration.
- For more detail on DocGo's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated ticker pages.
- You can also explore Trending AI Robots to see AI-driven trading strategies and market ideas.
Why These Results Matter Now
DocGo's third quarter 2026 results arrive at a pivotal moment for the mobile health and medical transportation provider. The company has spent the past year restructuring away from its former migrant-services business and refocusing on higher-margin core offerings such as medical transportation, remote patient monitoring, mobile phlebotomy, and virtual care through its SteadyMD acquisition. I’m watching closely to see whether these efforts translate into narrowing losses and a clearer path toward profitability. Because management has also guided to continued adjusted EBITDA losses through 2026, this report serves as a key checkpoint on execution, cost discipline, and cash management — factors that will shape sentiment as the company navigates a leadership transition and pursues additional acquisitions. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Reported Numbers
For the quarter ended September 30, 2026, DocGo reported total revenue of $73.4 million, a 3.7% increase from $70.8 million in the prior-year period, but below the consensus estimate of approximately $78.7 million. Revenue excluding migrant-related programs grew about 18% year over year, driven by the SteadyMD acquisition, which contributed roughly $7.8 million during the quarter.
Net loss was $18.1 million, an improvement from a net loss of $29.7 million in the third quarter of 2025. Adjusted EBITDA was a loss of $3.2 million, compared with a loss of $7.2 million a year earlier. On a per-share basis, the company reported a diluted loss of $0.17, wider than the roughly $0.09 loss that analysts had anticipated.
Gross margin showed progress. GAAP (Generally Accepted Accounting Principles) gross margin improved to 29.7% from 20.0%, while adjusted gross margin — which strips out depreciation and amortization — was 33.3%, roughly in line with 33.0% a year earlier. Medical transportation revenue reached $53.3 million, up 6.4% from $50.1 million, while Mobile Health revenue was $20.2 million, down slightly from $20.7 million. For the full year, management revised revenue guidance to approximately $300 million, down from $305 million to $310 million, citing the restructuring of unprofitable business lines, while reaffirming its adjusted EBITDA outlook of a $17 million to $22 million loss.
How the Market Reacted
DocGo shares fell roughly 6.6% in after-hours trading following the release, reflecting investor disappointment that revenue and per-share results both came in short of Wall Street's expectations. The mixed quarter highlighted the tension between steady operational progress and lingering losses: while medical transportation volumes reached record levels and gross margins improved, the company still posted a net loss and trimmed its revenue outlook. The simultaneous announcement of a CEO search added a layer of uncertainty for shareholders, even as management emphasized that the transition is being handled through an executive search firm and that Bienstock has agreed to remain through at least March 31, 2027 to support continuity.
What to Watch Going Forward
Looking ahead, investors will be watching whether DocGo can sustain its margin trajectory and reach the profitability milestones management has described. The company reaffirmed its full-year 2026 adjusted EBITDA guidance of a $17 million to $22 million loss, implying continued improvement in the fourth quarter and into 2027.
Several catalysts are worth monitoring. First, the pending acquisition of Hicuity Health is expected to close in late November or early December and is not yet included in revenue guidance, meaning it could add incremental scale to the Mobile Health segment. Second, the company's decision to wind down its unprofitable Upstate New York medical transportation market should remove a drag on gross margins going forward.
Cost pressures remain a factor to watch. Elevated fuel costs and aggressive hiring to support SteadyMD demand have restrained margins, and management's ability to normalize those expenses will be central to the profitability story. Finally, the leadership transition and any further restructuring or strategic alternatives activity could influence the pace and direction of the turnaround. As always, actual results will depend on execution, contract ramps with payer and provider partners, and broader healthcare and economic conditions. From what I see, one thing that stands out is how the Hicuity Health deal could shift the trajectory once it closes.
Using AI Tools in My Research
In my analysis of healthcare names like this, I often turn to Tickeron’s AI Screener to quickly filter for similar companies based on technical patterns and fundamentals. It helps surface comparable ideas without spending hours on manual reviews, which keeps my workflow efficient when evaluating turnaround stories like DocGo.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
DCGO's RSI Oscillator recovers from oversold territory
The RSI Oscillator for DCGO moved out of oversold territory on November 03, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 31 similar instances when the indicator left oversold territory. In 27 of the 31 cases the stock moved higher. This puts the odds of a move higher at 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 59 of 69 cases where DCGO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for DCGO just turned positive on November 03, 2026. Looking at past instances where DCGO's MACD turned positive, the stock continued to rise in 36 of 46 cases over the following month. The odds of a continued upward trend are 78%.
Following a +3.37% 3-day Advance, the price is estimated to grow further. Considering data from situations where DCGO advanced for three days, in 186 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
DCGO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DCGO as a result. In 78 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DCGO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for DCGO entered a downward trend on November 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.204) is normal, around the industry mean (204.532). P/E Ratio (-0.126) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.154) among similar stocks. P/S Ratio (0.127) is also within normal values, averaging (2.688).
The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. DCGO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DCGO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry HospitalNursingManagement
Advertisement